MIM
CTMX icon

MetLife Investment Management’s CytomX Therapeutics CTMX Stock Holding History

MetLife Investment Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-17,692
Closed -$47.2K – 2871
2022
Q1 		$47.2K Sell
17,692
-6,754
-28% -$25.9K ﹤0.01% 2680
2021
Q4 		$106K Buy
24,446
+14,566
+147% +$85.3K ﹤0.01% 2387
2021
Q3 		$50.3K Sell
9,880
-16,228
-62% -$86.9K ﹤0.01% 2532
2021
Q2 		$165K Buy
26,108
+20,846
+396% +$162K ﹤0.01% 2269
2021
Q1 		$40.7K Sell
5,262
-9,764
-65% -$77.3K ﹤0.01% 2286
2020
Q4 		$98.4K Hold
15,026
– – ﹤0.01% 2227
2020
Q3 		$99.9K Sell
15,026
-12,276
-45% -$91K ﹤0.01% 2211
2020
Q2 		$227K Hold
27,302
– – ﹤0.01% 1831
2020
Q1 		$209K Hold
27,302
– – ﹤0.01% 1674
2019
Q4 		$227K Hold
27,302
– – ﹤0.01% 1913
2019
Q3 		$201K Hold
27,302
– – ﹤0.01% 1939
2019
Q2 		$306K Buy
27,302
+9,012
+49% +$94.5K ﹤0.01% 1772
2019
Q1 		$197K Hold
18,290
– – ﹤0.01% 1993
2018
Q4 		$276K Hold
18,290
– – ﹤0.01% 1732
2018
Q3 		$338K Hold
18,290
– – ﹤0.01% 1782
2018
Q2 		$418K Buy
18,290
+4,831
+36% +$123K ﹤0.01% 1515
2018
Q1 		$383K Buy
13,459
+1,860
+16% +$53.1K ﹤0.01% 1538
2017
Q4 		$245K Buy
+11,599
New +$241K ﹤0.01% 1823

Other funds holding CTMX

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

MetLife Investment Management's CTMX Position: Q2 2022 in Review

MetLife Investment Management sold out of CytomX Therapeutics (CTMX) in Q2 2022, closing a stake of 17,692 shares — an estimated $47.2K sold.

MetLife Investment Management first reported a position in CTMX in Q4 2017 and held it in 18 quarters. The position peaked at $418K in Q2 2018. 98 funds tracked by Wall St. Rank hold CTMX as of Q2 2022.

  • MetLife Investment Management reported no remaining CytomX Therapeutics position as of Q2 2022 after selling out during the quarter.
  • MetLife Investment Management sold 17,692 CytomX Therapeutics shares in Q2 2022, an estimated $47.2K.
  • MetLife Investment Management first reported a position in CytomX Therapeutics in Q4 2017 and held it in 18 quarters.
  • MetLife Investment Management's CytomX Therapeutics position peaked at $418K in Q2 2018.
  • 98 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q2 2022.

Based on MetLife Investment Management's 13F filing for Q2 2022, filed 11 Aug 2022.